Compare EPR Properties (EPR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs TG Therapeutics Inc — how do they compare? EPR Properties trades at $54.74 (market cap $4.17B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and EPR Properties pays a 6.84% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and TG Therapeutics Inc for 16 Days on average.
| EPR | TGTX | |
|---|---|---|
Market Cap | $4.17B | $8.16B |
Volume | 992,716 | 1,735,121 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $59.06 |
52-Week Low | $48.71 | $26.94 |
Typical Hold Time | 46 Days | 16 Days |
Enterprise Value | $7.68B | $8.37B |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.74, up 1.22% today, with a bearish technical signal despite oversold RSI readings. The REIT reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Fundamentals show strong profitability with a 37.66% net income margin and a 6.5% dividend yield, supported by $421M in operating cash flow for 2025. Recent news highlights its appeal as a high-yield monthly dividend stock for retirees, with diversification into theme parks and fitness.
The outlook is cautiously optimistic, with a consensus price target of $65.50 implying 20% upside, though technical weakness and a projected net cash flow decline in 2026 pose risks. Investment opportunities include undervaluation relative to peers and resilient tenant performance, while risks involve interest rate sensitivity and execution of diversification strategy amid economic uncertainty.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
